AUROBINDO

August 3, 2026

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Business Responsibility & Sustainability Report for FY 2025-26

Pursuant to Regulations 34 (2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Business Responsibility & Sustainability Report of the Company for the Financial Year 2025-26.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.08.03 18:12:17 +05'30'
B. Adi Reddy
Company Secretary

Encl: as above.

(CIN : L24239TG1986PLC015190)
AUROBINDO PHARMA LIMITED
www.aurobindo.com
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Business Responsibility & Sustainability Report

Section A GENERAL DISCLOSURES

I- DETAILS OF LISTED ENTITIES

1.	Corporate Identity Number (CIN) of the Listed Entity	L24239TG1986PLC015190
2.	Name of the Listed Entity	Aurobindo Pharma Limited
3.	Year of incorporation	1986
4.	Registered office address	Plot no.2, Maithrivihar, Behind Maithrivanam, Ameerpet, Hyderabad - 500038, Telangana, India
5.	Corporate address	Galaxy, Floor 22-24; Plot No 1, Sy No 83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad - 500032, Telangana, India
6.	E-mail	info@aurobindo.com
7.	Telephone	040-66721200
8.	Website	www.aurobindo.com
9.	Financial year for which reporting is being done	2025-26
10.	Name of the Stock Exchange(s) where shares are listed	BSE Limited, National Stock Exchange of India Limited
11.	Paid-up Capital	INR 58,08,01,623
12.	Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report	Mr. B. Adi Reddy, Company Secretary & Compliance Officer Phone: +91 40 6672 5333 Email: cs@aurobindo.com
13.	Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together).	The disclosure under BRSR is on consolidated basis, unless otherwise stated
14.	Name of assurance provider	M/s. Sharp & Tannan Associates
15.	Type of assurance obtained	Reasonable Assurance

II – PRODUCTS AND SERVICES

16. Details of business activities (accounting for 90% of the Turnover)

Sl. No	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1	Manufacturing	Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products	100 %

17. Products/Services sold by the entity (accounting for 90% of the Entity's Turnover)

Sl. No	Product/Service	NIC Code	% of total Turnover contributed
1	Development, Manufacture and Sale of Active Pharma Ingredients and Formulations	21009	100%

III- OPERATIONS

18. Number of locations where plants and/or operations/offices of the entity are situated:

Location	Number of plants*	Number of offices	Total
National	28	3	31
International	5	52	57

* Note: 31 manufacturing facilities out of 33 are under commercial operations

AUROBINDO
Committed to healthier life!

19. Markets served by the entity:

A. Number of locations:

Locations	Number
National (No. of States and Union Territories)	28 States; 7 Union Territories
International (No. of Countries)	151 countries

B. What is the contribution of exports as a percentage of the total turnover of the entity?

91%

C. A brief on types of customers

Generic customers, Major pharma customers, Institutional customers and Health care professionals

IV – EMPLOYEES

20. Details as at the end of Financial Year

A. Employees and workers (including differently abled):

Sl. No	Particulars	Total	Male		Female	
			No.	%	No.	%
Employees						
1	Permanent	29,209	26,311	90%	2,898	10%
2	Other than Permanent	-	-	-	-	-
	Total employees	**29,209**	**26,311**	**90%**	**2,898**	**10%**
Workers						
1	Permanent	-	-	-	-	-
2	Other than Permanent	17,246	13,819	80%	3,427	20%
	Total workers	**17,246**	**13,819**	**80%**	**3,427**	**20%**

B. Differently abled Employees and workers:

Sl. No	Particulars	Total	Male		Female	
			No.	%	No.	%
Employees						
1	Permanent	3	3	100%	-	-
2	Other than Permanent	-	-	-	-	-
3	Total employees	3	3	100%	-	-
Workers						
4	Permanent	-	-	-	-	-
5	Other than Permanent	-	-	-	-	-
6	Total workers	-	-	-	-	-

21. Participation/Inclusion/Representation of women

Particulars	Total	No. and percentage of Females	
		No.	%
Board of Directors	9	1	11%
Key Management Personnel	4	-	-

22. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years)

Particulars	FY 2026			FY 2025			FY 2024		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	15%	19%	15%	13%	19%	13%	15%	28%	16%
Permanent Workers	-	-	-	-	-	-	-	-	-

V – HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES)

23. Names of holding / subsidiary / associate companies / joint ventures

Sl. No	Name of the holding /subsidiary / associate companies / joint ventures	Indicate whether holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1	Helix Healthcare B.V.	Subsidiary	100%	Yes
2	Agile Pharma B.V.	Subsidiary	100%	Yes
3	Aurex B.V. (Merged with Aurobindo Pharma B.V. w.e.f. 1st April, 2024)	Subsidiary	100%	Yes
4	Milpharm Limited	Subsidiary	100%	Yes
5	Aurobindo Pharma (Malta) Ltd	Subsidiary	100%	Yes
6	APL Swift Services (Malta) Ltd	Subsidiary	100%	Yes
7	Aurobindo Pharma (Romania) s.r.l	Subsidiary	100%	Yes
8	Pharmacin B.V. (formerly known as Aurex B.V.)	Subsidiary	100%	Yes
9	Aurovitas Pharma Polska	Subsidiary	100%	Yes
10	Generis Farmaceutica S.A.	Subsidiary	100%	Yes
11	Generis Phar, Unipessoal Lda	Subsidiary	100%	Yes
12	Aurobindo Pharma (Italia) S.r.l	Subsidiary	100%	Yes
13	Arrow Generiques SAS	Subsidiary	100%	Yes
14	1980 Puren Pharma GmbH (formerly Actavis Management GmbH), Germany	Subsidiary	100%	Yes
15	Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG)	Subsidiary	100%	Yes
16	Aurovitas Spain SA (formerly Actavis Spain S.A)	Subsidiary	100%	Yes
17	Aurobindo Pharma B.V. (formerly known as Actavis B.V.)	Subsidiary	100%	Yes
18	Aurovitas Spol s.r.o (formerly Apotex (CR) Spol s.r.o.)	Subsidiary	100%	Yes
19	Apotex Europe B.V.	Subsidiary	100%	Yes
20	Aurovitas Nederland B.V (formerly Apotex Nederland B.V.)	Subsidiary	100%	Yes
21	Sameko Farma B.V.	Subsidiary	100%	Yes
22	Leidapharm B.V.	Subsidiary	100%	Yes
23	Marel B.V.	Subsidiary	100%	Yes
24	Pharma Dossier B.V.	Subsidiary	100%	Yes
25	Aurobindo NV/SA	Subsidiary	100%	Yes
26	CuraTeQ Biologics s.r.o.	Subsidiary	100%	Yes
27	Eugia Pharma B.V.	Subsidiary	100%	Yes
28	Eugia Pharma (Malta) Limited	Subsidiary	100%	Yes
29	Eugia (UK) Limited	Subsidiary	100%	Yes
30	Ace Laboratories Limited (w.e.f 28 June 2024)	Subsidiary	100%	Yes
31	APL Pharma Thai Limited	Subsidiary	97.90%	Yes
32	Aurobindo Pharma Industria Farmaceutica Ltd	Subsidiary	99.97%	Yes
33	Aurobindo Pharma Produtos Farmaceuticos Limitada	Subsidiary	100%	Yes
34	All Pharma (Shanghai) Trading Co Ltd	Subsidiary	100%	Yes
35	Auro Pharma Inc.	Subsidiary	100%	Yes

Sl. No	Name of the holding /subsidiary / associate companies / joint ventures	Indicate whether holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
36	Aurobindo Pharma (Pty) Ltd	Subsidiary	100%	Yes
37	Purple Bellflower, South Africa (w.e.f. 30th April, 2024)	Subsidiary	100%	Yes
38	Aurobindo Pharma Japan K.K.	Subsidiary	100%	Yes
39	Aurovida Farmaceutica SA DE CV	Subsidiary	100%	Yes
40	Aurobindo Pharma Colombia S A S	Subsidiary	100%	Yes
41	Aurogen South Africa (PTY) Ltd	Subsidiary	100%	Yes
42	Aurobindo Pharma Saudi Arabia Limited Company	Subsidiary	100%	Yes
43	Aurovitas Pharma (Taizhou) Ltd	Subsidiary	100%	Yes
44	Aurobindo Pharma FZ LLC	Subsidiary	100%	Yes
45	Aurosalud SA De CV	Subsidiary	100%	Yes
46	Auro PR Inc	Subsidiary	100%	Yes
47	Eugia Pharma INC, Canada	Subsidiary	100%	Yes
48	Eugia Pharma (Australia) PTY Limited	Subsidiary	100%	Yes
49	Eugia Pharma Industria Farmaceutica Limitada	Subsidiary	100%	Yes
50	Aurobindo Pharma Ukraine LLC	Subsidiary	100%	Yes
51	Eugia Pharma Colombia S.A.S.	Subsidiary	100%	Yes
52	PT Aurogen Pharma Indonesia	Subsidiary	100%	Yes
53	Auro Pharma LLC, Russia (w.e.f. July 24, 2023)	Subsidiary	100%	Yes
54	Aurobindo Pharma USA., Inc.	Subsidiary	100%	Yes
55	Aurolife Pharma LLC	Subsidiary	100%	Yes
56	Auro Health LLC	Subsidiary	100%	Yes
57	Auro AR LLC	Subsidiary	100%	Yes
58	Auro Vaccines LLC	Subsidiary	100%	Yes
59	Auro Logistics LLC	Subsidiary	100%	Yes
60	Acrotech Biopharma Inc. (formerly Acrotech Biopharma LLC)	Subsidiary	100%	Yes
61	Auro Science LLC	Subsidiary	100%	Yes
62	Auro Packaging LLC	Subsidiary	100%	Yes
63	Vespyr Brands LLC (formerly known as Vespyr Brands, Inc.)	Subsidiary	100%	Yes
64	Eugia Inc	Subsidiary	100%	Yes
65	Eugia US LLC (formerly known as Auromedics Pharma LLC),U.S.A	Subsidiary	100%	Yes
66	Eugia US Manufacturing LLC	Subsidiary	100%	Yes
67	APL Healthcare Limited	Subsidiary	100%	Yes
68	Auro Peptides Ltd	Subsidiary	95%	Yes
69	Apitoria Pharma Private Limited (formerly Auro Pharma India Private Limited)	Subsidiary	100%	Yes
70	Auroactive Pharma Private Limited	Subsidiary	100%	Yes

Sl. No	Name of the holding /subsidiary / associate companies / joint ventures	Indicate whether holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
71	CuraTeQ Biologics Private Limited	Subsidiary	100%	Yes
72	Eugia Steriles Private Limited (formerly known as Auro Cure Private Limited)	Subsidiary	100%	Yes
73	AuroZest Private Limited	Subsidiary	100%	Yes
74	Aurobindo Antibiotics Private Limited	Subsidiary	100%	Yes
75	Eugia Pharma Specialities Limited	Subsidiary	100%	Yes
76	Lyfius Pharma Private Limited	Subsidiary	100%	Yes
77	Qule Pharma Private Limited	Subsidiary	100%	Yes
78	Eugia SEZ Private Limited (formerly Wytells Pharma Private Limited)	Subsidiary	100%	Yes
79	Auro Vaccines Private Limited	Subsidiary	100%	Yes
80	GLS Pharma Limited (w.e.f. 25th October, 2024)	Subsidiary	100%	Yes
81	TheraNyM Biologics Private Limited (w.e.f. 11th December, 2024)	Subsidiary	98%	Yes
82	Auro Trading Private Limited (w.e.f. 22nd November, 2023)	Subsidiary	100%	Yes
83	CuraTeQ Biologics B.V., Netherlands (Incorporated w.e.f. 28th May, 2025)	Subsidiary	100%	Yes
84	CuraTeQ Biologics (Malta) Limited (Incorporated w.e.f. 26th September, 2025)	Subsidiary	100%	Yes
85	Aurobindo Pharma (Malaysia) SDN. BHD. (w.e.f 27th September,2025)	Subsidiary	100%	Yes
86	Aurobindo Pharma Chile SpA (w.e.f 07th October, 2025)	Subsidiary	100%	Yes
87	Eugia Pharma Chile SpA (w.e.f 07th October, 2025)	Subsidiary	100%	Yes
88	Aurobindo Pharma Philippines Inc. (w.e.f 23rd January, 2026)	Subsidiary	100%	Yes
89	Diadame Pharma (w.e.f 01st January,2026)	Subsidiary	100%	Yes
90	Engenra Biologics Private Limited	Subsidiary	100%	Yes
91	Luoxin Aurovitas Pharm (Chengdu) Co., Ltd.	Joint Venture	30%	No
92	Raidurgam Developers Limited (formerly Aurobindo Antibiotics Limited)	Joint Venture	40%	No
93	Tergene Biotech Limited (formerly known as Tergene Biotech Private Limited)	Joint Venture	80%	No
94	NVNR (Ramannapet I) Power Plant Private Limited	Associate	26%	No
95	NVNR (Ramannapet II) Power Plant Private Limited	Associate	26%	No
96	Aurobindo Pharma Foundation	Sec 8 Company	100%	Yes

VI – CSR DETAILS

24.

(i)	Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No)	Yes
(ii)	Turnover (in Rs.)*	INR 33,653 Cr
(iii)	Net worth (in Rs.)*	INR 37,883 Cr

*Basis consolidated financial statements

VII-TRANSPARENCY AND DISCLOSURES COMPLIANCES

25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No)	(If Yes, then provide web-link for grievance redress policy)	FY 2026			FY 2025		
			Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	No. of complaints filed during the year	No. of complaints pending resolution at close of the year	Remarks
Communities	Yes		-	-	-	-	-	-
Investors and Shareholders	Yes *(V)		9	-	-	5	-	-
Employees and workers	Yes- People Care Link and others* (I,II,III,IV)		-	-	-	101	-	-
Consumers and Customers	Yes**		4,056	752	-	4,593	641	-
Suppliers	Yes*(I,II,V)		-	-	-	-	-	-

*Major policies guiding the responsible business conduct spanning key stakeholders are provided below

I. Policy on Business Ethics and Values (Link: https://www.aurobindo.com/api/uploads/Policy%20on%20Business%20Ethics%20&%20Values_Aurobindo%20Pharma%20Ltd.pdf)

II. Human Rights Policy
(Link: https://www.aurobindo.com/images/sustainablity/Human%20Rights%20Policy_Aurobindo%20Pharma%20Ltd.pdf)

III. Prevention of Sexual Harassment Policy (Available on Company Intranet portal)

IV. Whistle Blower Policy (https://www.aurobindo.com/api/uploads/Whistle%20Blower%20Policy-APL-New-March2024.pdf)

V. Supplier Code of Conduct
(Link: https://www.aurobindo.com/images/sustainablity/Supplier%20Code%20of%20Conduct_Aurobindo%20Pharma%20Ltd.pdf)

VI. Investor Grievance Redressal Policy (Link: https://www.aurobindo.com/api/uploads/Aurobindo-InvestorGrievanceRedressalPolicy09112024%20-Final.pdf)

** Consumers can report any adverse event involving any of the company's product through company's website (Link: https://www.aurobindo.com/contact-us/adverse-event-reporting)

26. Overview of the entity's material responsible business conduct issues

Material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications

Sl. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1	Energy Management	Risk and Opportunity	**Risk:** Rising energy costs, stringent regulatory targets on energy savings, and the transition from fossil fuels to renewables pose significant cost-related risks. Failure to address these risks could result in higher operational costs, non- compliance penalties and reputational damage. **Opportunity:** Energy efficiency initiatives can lower utility bills and operational costs. Aligning with evolving energy and carbon regulations can avoid penalties. Augmenting renewable energy's share can reduce exposure to energy price volatility and supply disruptions.	Upgrading to energy efficient technologies Conducting energy audits	Positive & Negative
2	Climate Change	Risk	• Stricter climate regulations, including renewable energy mandates and emissions reduction targets, pose transition risks, requiring higher compliance costs, operational changes and significant investments in low-carbon technologies and infrastructure Extreme weather events can disrupt supply chains, cause resource scarcity, and inflate raw material costs, critically impacting product distribution networks and business operations.	Transitioning to renewable energy Substituting coal with biomass	Negative
3	Workforce Wellbeing	Risk and Opportunity	**Risk:** A dynamic and highly competitive job market poses talent attraction and retention challenges. Limited growth opportunities or skill mismatches can lead to disengagement, increased attrition, and productivity loss over time. **Opportunity:** Investing in digital-first learning systems, hybrid work models, and personalised career development can help address generational expectations and promote long-term workforce sustainability. A strong, well-being culture also supports our employer brand and stakeholder confidence.	Robust learning and development ecosystem Employee engagement initiatives like Chai Pe Charcha, Auro Josh, and Leadership Talk Series Structured child development programs (Saksham), and safety-linked rewards	Positive and Negative

Sl. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
4	Corporate Governance	Opportunity	Alignment with evolving ESG disclosure mandates, such as EU CSRD and SEBI regulations improves company's brand image and engagement with diverse stakeholders	-	Positive
5	Product Stewardship	Risk and Opportunity	**Risk:** Non-compliance with the applicable regulatory requirements such as the US FDA, EMA, MHRA and WHO. The US and EU's strict regulations on product packaging, can lead to expensive product recalls and reputational damage. Transitioning to sustainable practices demands significant upfront investments in new technologies, processes, or materials, straining financial resources. Sourcing sustainable materials or partnering with suppliers compliant with product stewardship principles may also inflate costs, impacting overall profitability. **Opportunity:** The Company acknowledges environmental responsibility and conducts Product Carbon Footprint (PCF) assessments to reduce the environmental impact of its products. This proactive stance positions the Company as a sustainability leader, enhances its reputation, and strengthens long-term customer relationships by aligning with their carbon reduction goals.	Yes, we are complying with applicable regulatory requirements such as the US FDA, EMA, MHRA and WHO. We also comply with the strict product quality requirements of the US, EU and other markets. Carrying out Product Carbon Footprint analysis of the key products	Positive and Negative
6	Occupational Health and Safety	Risk	Gaps in adherence to safety protocols, lack of real-time monitoring, or insufficient training risk recurring safety failures, leading to enforcement actions and reputational damage.	• Obtaining the ISO 45001:2018 certification for the plants Safety committees are in place Prioritising training our employees and contractors on occupational health and safety	Negative
7	Water Management	Opportunity	Water reuse and recycling through ZLD, rainwater harvesting, and groundwater recharge present significant opportunities for cost savings, resource efficiency, and long-term water security while ensuring compliance with regulations and targets.	-	Positive

Sl. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
8	Sustainable Supply Chain	Risk and Opportunity	**Risk:** Climate disruptions, such as extreme weather events and resource scarcity, may lead to higher raw materials and logistics costs. Instances of forced labour, child labour, excessive working hours, etc, incur legal penalties. With stricter regulations globally, such as India's BRSR Core and the EU's CSDDD, demanding extensive supply chain-related disclosures, significant investment in process setup and reporting systems is required. **Opportunity:** Investing in sustainable practices helps companies secure their long-term viability, effectively responding to the changing market trends and consumer preferences.	Supplier Code of Conduct in place Prioritising local sourcing as a key business objective Rigorous supplier evaluation process includes assessing credibility, environmental procedures, manufacturing techniques, and commitment to environmentally friendly practices	Positive and Negative
9	Antimicrobial Resistance	Risk	Improper management of antibiotic waste during manufacturing can release active pharmaceutical ingredients (APIs) into the environment, contaminating aquatic ecosystems with trace drug residues. This disrupts aquatic life, threatens biodiversity, and fuels antimicrobial resistance (AMR), a growing global public health and environmental crisis. Effective and scalable solutions to manage this risk are still being sought.	Member of the 'AMR Industry Alliance,' which is driving antimicrobial resistance progress via common objectives and commitment to increase access to high-quality antimicrobial products, encourage responsible usage, and reduce environmental concerns.	Negative
10	Waste Management and Material Efficiency	Risk	Irresponsible waste management and inefficient material consumption can risk environmental non-compliance, leading to financial penalties and reputational damage. With tightening policies, such as the EU's Regulation (EU) 2025/40, which mandates stricter controls on packaging waste and promotes circular economy principles, APL may also face increased scrutiny from stakeholders and investors.	Co-processing of hazardous waste Packaging optimisation to reduce the plastic waste	Negative
11	Inclusion, Diversity and Equality	Opportunity	A diverse workforce ignites creativity and innovation by bringing together individuals with different backgrounds, experiences, and perspectives. Inclusive workplaces enhance employee satisfaction and retention rates, significantly reducing turnover costs.		Positive

AUROBINDO
Committed to healthier life!

Section B MANAGEMENT AND PROCESS DISCLOSURES

Disclosure Question	P-1	P-2	P-3	P-4	P-5	P-6	P-7	P-8	P-9
1. A. Whether your entity's policy/ policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Yes						-	Yes	
1. B. Has the policy been approved by the Board? (Yes/No)	Yes							Yes	
1. C. Web Link of the Policies, if available	https://www.aurobindo.com/sustainability/social-accountability-standards https://www.aurobindo.com/investors/corporate-governance/governance-policies https://www.aurobindo.com/sustainability/our-commitment https://www.aurobindo.com/api/uploads/Policy%20on%20Business%20Ethics%20&%20Values_Aurobindo%20Pharma%20Ltd.pdf https://www.aurobindo.com/pdfs/Human%20Rights%20Policy_Aurobindo%20Pharma%20Ltd.pdf https://www.aurobindo.com/pdfs/Supplier%20Code%20of%20Conduct_Aurobindo%20Pharma%20Ltd.pdf								
2. Whether the entity has translated the policy into procedures. (Yes/No)	Yes						-	Yes	
3. Do the enlisted policies extend to your value chain partners? (Yes/No)	Yes. Policy on Business Ethics and Values, Human Rights Policy and Supplier Code of Conduct extend to value chain partners							-	
4. Name of the national and international codes/certifications/ labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	SA 8000 ISO 45001:2018	ISO 14001: 2015	SA 8000 ISO 45001:2018	-	SA 8000 ISO 45001:2018	ISO 14001: 2015	-	-	ISO9001: 2015 ISO 27001:2022
5. Specific commitments, goals and targets set by the entity with defined timelines, if any.	Note 1								
6. Performance of the entity against the specific commitments, goals and targets along-with reasons in case the same are not met.									

Note 1

Pillar		2025-2030 goals	Progress made so far
Responsible Manufacturing	i.	40% renewable energy share (Power-to-Power) – (Baseline year – 2025)	18.4%
	ii.	25% reduction in carbon footprint (Scope 1 and 2) – (Baseline year – 2025)	Increase in emissions because of business growth and higher production output from the recently commercialized Lyfius and Qule facilities.
	iii.	Towards water neutrality – 70% water conservation/restoration – (Baseline year – 2025)	54%
	iv.	70% co-processing of hazardous waste	66%
	v.	100% reuse / recycle of non-hazardous waste	100%
	vi.	Obtaining Antimicrobial Resistance (AMR) certification from BSI by 2030 for β-Lactam and Cephalosporins	In progress

Pillar	2025-2030 goals		Progress made so far
Sustainable Sourcing	i.	100% of key starting material suppliers of Top 50 products (by Revenue) in India of finished dosage forms- FDF (drug product) shall be assessed on Suppliers' Code of Conduct as per Pharmaceutical Supply Chain Initiative (PSCI) principles – Ongoing	77%
	ii.	Embedding our commitments in our supply chain – Supplier evaluation and selection process to include appropriate weightage for Environmental and Social (ES) criteria and develop contract clauses to address reduction in ES impact	In progress
	iii.	Key Starting Material suppliers of Top 50 products (By Revenue) to reduce their Scope-1 and Scope-2 emission by 10% by 2030.	In progress
Supply Chain Scope-3 Emission reduction	i.	25% Transition to low carbon/electric vehicles for employee transportation (Company Buses / Company-owned vehicles)	In progress
	ii.	>90% transition from Air to Sea freight for downstream transportation of finished products for Top 100 products	Achieved
	iii.	10% Transition to low carbon / electric transportation by 2030 (Baseline year- 2025) for upstream logistics for key raw materials (Road vehicles, Sea transportation and Air)	In progress
Social Equity	i.	19% women workforce in non-core areas out of total workforce in non-core areas (Already achieved 14.5% in non-core areas).	16.61%
	ii.	An average 40 hours of learning per employee / Annum including: • 20 hours online Artificial Intelligence (AI) / Digital, Web-based trainings. • • 20 hours mandatory training for each employee.	27

Governance, leadership and oversight

7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements

With over three decades of experience, world-class infrastructure, and a talented team, we at Aurobindo Pharma are committed to creating value for all our stakeholders. We are diligently integrating ESG at the core of our functioning and in all that we do.

For Aurobindo pharma, sustainability means adhering to responsible business practices and consistent involvement with all stakeholders. We strive to achieve economic success, while having business policies that are ethical, equitable, environmentally conscious, and sensitive towards the differently abled. We have made progress in terms of gender diversity among our workforce with a strong focus on employee learning & development.

Reducing carbon footprint through use of renewable energy and building resilient solutions that empower disadvantaged communities are some of our key priorities within the ESG framework. and 18.4% share of renewable energy.

In FY26, we consumed total of 1,70,250 MWh renewable power which include self-generated solar power at our manufacturing facilities and purchased solar power from our Associate companies. We generated about 50,791 MWh solar power from our captive power plant at Pydibhimavaram, Vizag and 1,19,459 MWh of solar power was purchased from associate companies.

Aurobindo Pharma commits itself to create a more equitable and inclusive society, through sustainable transformation and social integration

8.	**Details of the highest authority responsible for implementation and oversight of the Business Responsibility policies**	Mr. K. Nithyananda Reddy Vice Chairman & Managing Director Telephone number: 040-6672 5101 E-mail ID: secretarial@aurobindo.com
9.	**Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No) If yes, provide details.**	Yes – ESG and Sustainability Committee

Name of the director	DIN Number	Designation
Dr. M. Madan Mohan Reddy	01284266	Chairperson
Mr. Mangalam Ramasubramanian Kumar	03628755	Member
Mr. Santanu Mukherjee	07716452	Member
Mr. K. Nithyananda Reddy	01284195	Member

Subject for Review and Independent Assessment	P1	P2	P3	P4	P5	P6	P7	P8	P9
10. Performance against above policies and follow up action	Yes. ESG and Sustainability Committee oversees compliance to these principles in periodic meetings								
Compliance with statutory requirements of relevance to the principles and rectification of any non-compliances	Audit Committee reviews the reports submitted by the internal auditors covering the above principles subject to the scope approved by Audit Committee								
11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide name of the agency.	Yes. Risk Management & Internal Audit reviews the adherence with support of external service providers. Scope is defined by the Risk Management & Internal Audit team and approved by Audit Committee								

12. If answer to question (1) above is "No" i.e. not all Principles are covered by a policy, reasons to be stated:

Not Applicable

Section C | PRINCIPLE WISE PERFORMANCE DISCLOSURE

Principle 1 | Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable

Section	Principle	Indicator Type
Section C	Principle 1	Essential Indicators

1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year:

Segment	Total number of training and awareness programmes held	Topics/principles covered under the training and its impact	%age of persons in respective category covered by the awareness programmes
Board of Directors (BOD)	3	Most of the familiarisation programmes are provided to Board of Directors and Key Managerial Personnel as a part of Board or Committee Meetings	100%
Key Managerial Personnel (KMP)	3		
Employees Other than BOD and KMPs	1	Employees undergo training covering the below topics i. Code of Conduct ii. Policy on Business Ethics and Values iii. Prevention of Sexual Harassment iv. Human Rights Policy v. Whistle Blower Policy vi. Environment, Health, Safety and Sustainability Policy vii. Policy on Staff Accountability Refresher training is imparted to existing employees majorly covering above topics once in a calendar year Employees basis their role undergo various training programs throughout the year. This includes cGMP trainings, functional SOP trainings, Safety trainings, On the Job trainings	100%
Workers	1	Health, Safety , Environmental and Sustainability trainings,code of conduct policy on business ethics and values and human rights policy, prevention of sexual harassment policy	100%

2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website):

Monetary

Particulars	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (INR)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty/Fine			Nil		
Settlement					
Compounding Fees					

Non – Monetary

Particulars	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (INR)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Imprisonment			Nil		
Punishment					

3. **Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed.**

Not Applicable

4. **Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy.**

Yes, The company has 'Policy on Business Ethics & Values' in place. The scope of the policy broadly covers Anti-Money laundering and Anti-Competitive Practices. The company is committed to conduct business in an ethical and honest manner, to implement and enforce the systems that ensure bribery and corruption are prevented. The company respects all laws relating to anti-bribery and anti-corruption in all the jurisdictions in which company operates.

The policy is applicable to all employees including contractual associates, third party contractors, sub-contractors, suppliers/vendors, and other service providers associated with the Company and its Subsidiaries located in India

5. **Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:**

Particulars	FY 2026	FY 2025
Directors	-	-
KMPs	-	-
Employees	-	-
Workers	-	-

6. **Details of complaints with regard to conflict of interest:**

Particulars	FY 2026		FY 2025	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	-	-	-	-
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	-	-	-	-

7. **Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.**

Not Applicable

8. **Number of days of accounts payables**

((Accounts payable *365) / Cost of goods/services procured) in the following format:

Particulars	FY26	FY25
Number of days of accounts payables	127 days	100 days

9. **Openness of business**

Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties, in the following format:

Parameter	Metrics		FY26	FY25
Concentration of Purchases	a.	Purchases from trading houses as % of total purchases	14.32 %	19.61%
	b.	Number of trading houses where purchases are made from	138	138
	c.	Purchases from top 10 trading houses as % of total purchases from trading houses	61.93%	66%

Parameter	Metrics		FY26	FY25
Concentration of Sales	a.	Sales to dealers / distributors as % of total sales	65.99%	45.16%
	b.	Number of dealers / distributors to whom sales are made	658	777
	c.	Sales to top 10 dealers / distributors as % of total sales to dealers / distributors	51.10%	49.88%
Share of RPTs in	a.	Purchases (Purchases with related parties /Total Purchases)	5.41%	5.45%
	b.	Sales (Sales to related parties /Total Sales)	0.02%	0.04%
	c.	Loans & advances (Loans & advances given to related parties /Total loans & advances)	-	-
	d.	Investments (Investments in related parties / Total Investments made)	4.10%	6.67%

Section	Principle	Indicator Type
Section C	Principle 1	Leadership Indicators

1. Awareness programmes conducted for value chain partners on any of the Principles during the financial year:

Sl. No	Total number of awareness programmes held	Topics/principles cover under the training	Percentage of value chain partners (by value of business done with such partners) under the awareness programmes
1	1	Supplier Code of conduct	77%*

*Supplier code of conducthas been communicated and awareness training programmes also conducted for 77% of key starting material suppliers (API) Further, value chain partners are expected to comply with Policy on Business Ethics and Values and Human Rights Policy

2. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No) If Yes, provide details of the same.

Yes, the company has 'Code of Conduct for Board Members and Senior Management Personnel' and 'Related Party Transaction Policy' in place.

Code of Conduct broadly covers matters pertaining to Conflict of interest, Honest and Ethical Conduct, Compliance with Laws, Rules and Regulations, Confidentiality, Protection and Proper Use of Company's Assets and Duties of Independent Director.

Link : https://www.aurobindo.com/investors/disclosures-under-regulation-46/code-of-conduct

Related Party Transactions Policy ensures that proper approval and reporting of transactions between the Company and its related parties in the best interest of the Company and its Stakeholders

Link : https://www.aurobindo.com/api/uploads/Related-Party-Transaction-Policy.pdf

Principle 2 — Businesses should provide goods and services in a manner that is sustainable and safe

Section	Principle	Indicator Type
Section C	Principle 2	Essential Indicators

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

Particulars	FY25	FY25	Details of improvements in environmental and social impacts
R&D	-	-	-
Capex	0.26%	0.62%	Focused on Environmental performance improvement with respect to Water and Energy conservation, environment, health and safety initiatives.

2. A. Does the entity have procedures in place for sustainable sourcing? (Yes/No)

Yes. Sustainable Procurement policy is in place.

B. If yes, what percentage of inputs were sourced sustainably?

Critical Suppliers of the company are evaluated basis the vendor qualification criteria outlined in the vendor qualification procedure. About 77% of key starting material suppliers for finished dosage forms (drug products) in India are following sustainable practices.

3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for

(a) Plastics (including packaging)

(b) e-waste

(c) Hazardous waste and

(d) Other waste

The company has Waste Management Systems in place at all manufacturing facilities for effective waste management.

(a) Plastic waste generated from packing material of expired material/market returns are sent to authorized recyclers for disposal

(b) 100% of e-waste generated is sold to authorized vendors.

(c) Reusable portion of Hazardous waste is sent to authorised Cement Industries for use as alternate fuel. Non-reusable portion of Hazardous waste is sent to authorised Treatment, Storage and Disposal Facility (TSDF) for Secured Landfills (SLFs).

(d) Other non-hazardous waste such as

i. Glass, MS scrap are sent to recyclers

ii. Boiler Ash is sent to brick manufacturers

iii. Batteries are sent to recyclers under buy-back programmes for batteries

iv. Biomedical Waste are sent to authorised waste management facility

4. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.

Yes, Extended Producer Responsibility (EPR) is applicable to the entity's activities. Yes, the waste collection plan is in line with the EPR plan submitted to Pollution Control Board

Section	Principle	Indicator Type
Section C	Principle 2	Leadership Indicators

1. Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? If yes, provide details?

Company has completed product carbon footprint analysis for three of its products. However, life cycle assessment is yet to be initiated.

2. If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same.

Not Applicable

3. **Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry).**

   Not Applicable

4. **Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely disposed**

   Not Applicable

5. **Reclaimed products and their packaging materials (as percentage of products sold) for each product category**

   Not Applicable

Principle 3	Businesses should respect and promote the well-being of all employees, including those in their value chains

Section	Principle	Indicator Type
Section C	Principle 3	Essential Indicators

1A. Details of measures for well-being of employees

Category	Total	% of employees covered by									
		Health insurance		Accident insurance		Maternity Benefits		Paternity Benefits		Day Care facilities	
		Number	%	Number	%	Number	%	Number	%	Number	%
Permanent Employees											
Male	26,311	26,311	100%	26,311	100%	-	-	-	-	24,228	92%
Female	2,898	2,898	100%	2,898	100%	2,898	100%	-	-	2,841	98%
Total	**29,209**	**29,209**	**100%**	**29,209**	**100%**	**2,898**	**100%**	**-**	**-**	**22,653**	**93%**
Other than Permanent Employees											
Male	-	-	-	-	-	-	-	-	-	-	-
Female	-	-	-	-	-	-	-	-	-	-	-
Total	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**

Note: Employees covered under ESI Act were categorised under health insurance. Total is taken basis head count as on 31st March,2026. Day care facility/crech. Check male vs female day care facility available/availing.

1B. Details of measures for the well-being of workers

Category	Total	% of workers covered by									
		Health insurance		Accident insurance		Maternity Benefits		Paternity Benefits		Day Care facilities	
		Number	%	Number	%	Number	%	Number	%	Number	%
Permanent Workers											
Male	-	-	-	-	-	-	-	-	-	-	-
Female	-	-	-	-	-	-	-	-	-	-	-
Total	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
Other than Permanent Workers											
Male	13,819	13,819	100%	13,819	100%	-		-	-	11,855	86%
Female	3,427	3,427	100%	3,427	100%	3,427	100%	-	-	3,308	97%
Total	**17,246**	**17,246**	**100%**	**17,246**	**100%**	**3,427**	**100%**	**-**	**-**	**15,163**	**88%**

1C. Spending on measures towards well-being of employees and (including permanent and other than permanent) in the following format

	FY26	FY25
Cost incurred on well-being measures as a % of total revenue of the company	0.65%	0.38%

2. Details of retirement benefits, for Current FY and Previous Financial Year

Benefits	FY 2026			FY 2025		
	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)
PF	100%	100%	Y	100%	100%	Y
Gratuity	43%	0%	NA	42%	0%	NA
ESI	17%	100%	Y	13%	100%	Y
Others- Social Security Contributions as per laws of the respective countries	100%	0%	Y	100%	0%	Y

Note: Coverage under PF and social security contributions is provided basis applicability of respective laws of country in which the entities operate

3. Accessibility of workplaces

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard

Yes, company's premises has sufficient infrastructure for differently abled persons.

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy

Yes, Clauses on equal opportunity are part of handbook of Aurobindo's Corporate Values provided to the employees at the time of formal joining of the company

5. Return to work and Retention rates of permanent employees and workers that took parental leave.

Gender	Permanent employees		Permanent workers	
	Return to work rate	Retention rate	Return to work rate	Retention rate
Male	-	-	-	-
Female	52%	100%	-	-
Total	**52%**	**100%**	**-**	**-**

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? If yes, give details of the mechanism in brief.

Category	Yes/No/NA
Permanent Workers	NA
Other than Permanent Workers	Yes
Permanent Employees	Yes
Other than Permanent Employees	Yes

Yes. Vigil Mechanism/Whistle Blower Policy of the company has adequate grievance redressal mechanism in place to report significant deviations from key management policies and report any non-compliance and wrong Practices, e.g., unethical behaviour, fraud, violation of law, inappropriate behaviour /conduct etc. Complainant shall address 'Protected disclosure under Whistle Blower Policy' to Vigilance and Ethics Officer or to the Audit Committee/CEO/Chairman in exceptional cases.

Apart from above, POSH committee, works committee, welfare and canteen committee are in place to address the grievances of workers and employees.

7. Membership of employees and worker in association(s) or Unions recognised by the listed entity:

Category	FY 2026			FY 2025		
	Total employees / workers in respective category	No. of employees / workers in respective category, who are part of association(s) or Union	%	Total employees / workers in respective category	No. of employees / workers in respective category, who are part of association(s) or Union	%
Total Permanent Employees						
- Male	26,311	-	-	24,965	13	-
- Female	2,898	-	-	2,742	-	-
Total Permanent Workers						
- Male	-	-	-	-	-	-
- Female	-	-	-	-	-	-

8. Details of training given to employees and workers:

Category	FY 2026					FY 2025				
	Total	On Health and safety measures		On Skill upgradation		Total	On Health and safety measures		On Skill upgradation	
		No.	%	No.	%		No.	%	No.	%
Employees										
Male	26,311	26,311	100%	26,311	100%	24,965	24,965	100%	24,965	100%
Female	2,898	2,898	100%	2,898	100%	2,742	2,742	100%	2,742	100%
Total	29,209	29,209	100%	29,209	100%	27,707	27,707	100%	27,707	100%
Workers										
Male	13,819	13,819	100%	-		10,653	10,653	100%	-	-
Female	3,427	3,427	100%	-	-	2,390	2,390	100%	-	-
Total	**17,246**	**17,246**	**100%**	**-**	**-**	**13,043**	**13,043**	**100%**	**-**	**-**

9. Details of performance and career development reviews of employees and worker:

Category	FY 2026			FY 2025		
	Total	No.	%	Total	No.	%
Employees						
Male	26,311	26,311	100%	24,965	24,965	100%
Female	2,898	2,898	100%	2,742	2,742	100%
Workers						
Male	-	-	-	-	-	-
Female	-	-	-	-	-	-

10. Health and safety management system:

a.	Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage such system?	Yes. The company has implemented an Occupational health and safety management system. The coverage is 100% of our facilities, and it covers both regular employees and contractors. Health, safety, and well-being of employees and associates are a crucial material topic for the company. The company is committed towards instilling a healthy lifestyle, a safe working environment, and a healthy work-life balance. EHS framework and management practices assure compliance while prioritising product and process safety and safeguarding all employees. Each manufacturing facility has departmental and Apex safety committee. Every month Management review meetings are conducted which comprises top management from Corporate and representatives from all sites including site heads to examine safety performance and streamline operational procedures critical to safety requirements. Health and safety training is provided to both permanent and contractual workers, ensuring that our team understands the significance of safe procedures and guidelines. Risk identification and assessments are undertaken as part of the process before scaling up. Before commencing any chemical process in the manufacturing area, a hazard and operability study (HAZOP) is conducted. For all new projects, existing production units, and distribution centres among others, the Company observes and monitors the safety laws and procedures.

b.	What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?	The company has developed a corporate guidance document which provides the course on how to identify, evaluate occupational Health and Safety risks, and reduce them to an acceptable level by strengthening existing controls and/ or incorporating additional controls for all the activities within the facilities of the organization. The Company undertakes periodic internal audits to ensure the compliance of Occupational Health and Safety management system within the manufacturing operation. The EHS trainings, audits and inspections are carried out as per the corporate guidelines. Further, it enables the identification of work-related hazards through design checklists, Hazard and Operability Analysis (HAZOP), Hazard Identification and Risk Assessment (HIRA), Activity based Risk Assessment. The guidelines clearly outline the role and responsibilities of individuals directly involved in identifying and mitigating Health & Safety risks on routine and non-routine basis.
c.	Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks. (Y/N)	Yes. The Company has well-established Standard Operating Procedures (SOP) for employees and workers to identify and report on work-related hazards and the subsequent steps to mitigate them. In addition, the Company trains all its employees and workers with occupational health and safety Standard operating procedures and work instructions. The training modules cover aspects of the methodology to identify work-related hazards, analyse the risks associated with it and take subsequent steps to mitigate them. During the safety and emergency evacuation drills, employees are trained in dealing with emergency equipment such as fire hydrant, firefighting system, leak and spill control procedures, safety alarms among others. In addition, the proficiency of employees is periodically tested in dealing with the emergency situations. The practical trainings and online safety modules equip the employees with right procedure of reporting work-related hazards and the steps to remove themselves from such situations
d.	Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? (Yes/ No)	Yes. The company provides non-occupational medical and healthcare services to its employees and workers. Further, the Company ensures the provision of medical insurance to all its employees and workers. With the endeavour to promote physical and mental wellbeing for all the employees and workers, the Company designs comprehensive health programs which promote healthy lifestyle practices.

11. Details of safety related incidents:

Safety Incident/Number	Category	FY 2026	FY 2025
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)	Employees	0.011	0.04
	Workers	0.033	
Total recordable work-related injuries	Employees	-	4
	Workers	2	
No. of fatalities	Employees	-	2
	Workers	1	
High consequence work-related injury or ill-health (excluding fatalities)	Employees	-	-
	Workers	-	

12. Describe the measures taken by the entity to ensure a safe and healthy workplace.

The company is committed towards instilling a healthy lifestyle, a safe working environment, and a healthy work-life balance. The EHS policy advocates the provision of safe working environment to all the employees, contractors, sub-contractors, visitors, and the neighbouring communities. EHS framework and management practices assure compliance while prioritising product and process safety and safeguarding all employees. Each manufacturing facility has departmental and Apex safety committee. Every month Management review meetings are conducted which comprises top management from Corporate and representatives from all sites including site heads to examine safety performance and streamline operational procedures critical to safety requirements. The Company undertakes periodic internal audits to assess the safety practices and procedures in alignment with the EHS management system and corporate EHS guidelines. As part of the auditing procedure and regular inspections, site visits, the Company recognises the critical areas requiring immediate corrective action.

The safety incidents and hazards are analysed to determine the root cause, subsequently corrective action plans are laid out to prevent the occurrence of similar incidents in the future. Further, as part of the EHS management system, the Company provides safety trainings through modules and safety drill practices to all its employees and workers. The safety training programs enable the development of strong foundation among the workforce, in terms of their ability to identify, mitigate and prevent risks pertaining to Occupational Health and Safety. The Company endeavours to prevent negative health impact on the employees through various health awareness sessions, provision of medical facilities and medical insurance benefits.

13. Number of Complaints on the following made by employees and workers:

Particulars	FY 2026			FY 2025		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working Conditions	-	-	-	-	-	-
Health & Safety	-	-	-	-	-	-

14. Assessments for the year:

Particulars	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Health and safety practices	100% of the manufacturing and R&D locations are audited internally by the entity. The audits are conducted by internal experts to ensure the compliance of safety regulations and identification of major improvement areas. Apart from internal audits, periodic assessments are also done by customers, third parties and statutory authorities.
Working Conditions	100% (All the sites are assessed on their working conditions by the internal audits)

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.

In general, post analysis of root cause of the incident, corrective and preventive actions are taken to avoid the occurrence of such incidents in the future.

Section	Principle	Indicator Type
Section C	Principle 3	Leadership Indicators

1. Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees (Y/N) (B) Workers (Y/N).

Yes

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners.

The Company has adequate mechanisms to ensure that requisite statutory dues, as applicable to the transactions of the Company with its value chain partners, are deducted and deposited in accordance applicable regulations. The Company has adequate systems in place to ensures payment of wages as per statute and statutory dues like PF, ESIC, etc. pertaining to contract workmen deployed through contractor.

The Company through its policy on business ethics and values, expects its value chain partners to conduct business in an ethical and honest manner, act professionally unbiased with integrity in all business dealings and ensure compliance to applicable laws and regulations

3. Provide the number of employees / workers having suffered high consequence work- related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:

Particulars	Total no. of affected employees/ workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 2026	FY 2025	FY 2026	FY 2025
Employees	-	-	-	-
Workers	-	-	-	-

4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No)

No

5. **Details on assessment of value chain partners:**

Particulars	% of value chain partners (by value of business done with such partners) that were assessed
Health and safety practices Working Conditions	Assessment of 100% of critical suppliers is made as a part of vendor qualification procedure and periodic vendor audits as per respective SOPs and Supplier Code of Conduct

6. **Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners.**

No significant risks/concerns arising from assessment of health and safety practices and working conditions of value chain partners

Principle 4 Businesses should respect the interests of and be responsive to all its stakeholders

Section	Principle	Indicator Type
Section C	Principle 4	Essential Indicators

1. **Describe the processes for identifying key stakeholder groups of the entity.**

Identifying key stakeholder groups are crucial for effective stakeholder management. Key stakeholders identified in consultation with the management are investor/shareholder, customers, suppliers, third party manufacturers, employees, communities, and NGOs.

2. **List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.**

Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of Communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website, Others)	Frequency of engagement (Annually/Half yearly/Quarterly/ others	Purpose and scope of engagement including key topics and concerns raised during such engagement
Investor/ shareholder	No	i. Website ii. Quarterly results and Annual reports iii. Press Release and Intimation to stock exchanges iv. Investor meetings/ conference	Quarterly result/ conference call – Quarterly Annual report – Annual Press release/ investor meetings – Need based	Investors/ Shareholders who form part of larger stakeholder group influence key decisions of the Company. Key topics for engagement with Investor/shareholders • Business Performance • Responsible business conduct • Corporate governance • Compliance with applicable laws and regulations • Strategic decisions in line with the vision and mission of the company
Customers	No	• In-person meetings including site visits • E-mail • Telephonic conversations • Business Conference	Need based (Ongoing)	Key interest areas of customer include: • Product quality • Product pricing • On time delivery • Logistics facility • Credit availability
Supplier/ Vendor/ Third party manufacturer	No	• In-person meetings including site visits • Vendor audits • E-mail • Telephonic conversations • Business Conference	Need based (Ongoing)	Key interest areas of supplier include: • Product quality & compliance • Timely payments • Responsible Supply Chain

Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of Communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website, Others)	Frequency of engagement (Annually/Half yearly/Quarterly/ others	Purpose and scope of engagement including key topics and concerns raised during such engagement
Government and Regulators	No	• In-person meetings • Facility audit • E-mail • Industry forums	Need based (Ongoing)	Key areas of interest for the regulators are: • Policy and Regulatory Affairs • Product filing and approvals • Compliance with laws and regulations
Employees	No	• In person meetings • Company intranet • E-mail • Notice Board • Auro Pulse Newsletter	Need based (Ongoing)	Key areas of interest for employees are: • Performance review • Employee welfare and wellbeing • Rewards, Benefits and Recognition • Skill based and behavioural learnings • Work-life balance • Fair salary compensation
Communities and Implementing Partners/NGOs	Yes	• In-person meetings • E-mail • Community Meetings • Request letters • Project Progress report	Need based (Ongoing)	Design, formulate, implement and monitor CSR project/activity scope based on need assessment

Section	Principle	Indicator Type
Section C	Principle 4	Leadership Indicators

1. **Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.**

   Respective functional heads engage with stakeholder groups on matters pertaining to economic, environmental and social topics. Any identified material issues post consultation with relevant stakeholders is brought to the notice of Board for appropriate further course of action

2. **Whether stakeholder consultation is used to support the identification and management of environmental, and social topics (Yes / No). If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.**

   Yes, the identification and management of material issues relevant to the environment, social, economic and governance topics is done in consultation with the stakeholders. Identified material issues along with financial and non-financial impact and further approach form part of materiality assessment in the Sustainability Report.

   For communities, stakeholder consultation is taken up through need assessments. This will identify the felt needs of the communities while impact assessments which are conducted one year after project completion highlight the impact of the project and identify challenges, if any, and contribute to future project planning. Furthermore, continuous interaction with the key stakeholder groups are imperative for the efficient implementation of the project to ensure the project creates a significant impact on the key stakeholders while also ensuring project sustainability.

3. **Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups.**

For every CSR Project, engagement with vulnerable/marginalized stakeholder groups is essential. It begins with identifying and assessing the felt needs of the communities through interactions with the communities and key representatives. The communities are also involved in the project implementation and monitoring phases which encourages the communities to take ownership of the project after its completion.

For example, the rural development projects of Aurobindo Pharma Foundation are focused on improving the rural infrastructure. Many villages lack proper roads and streetlights which not only impact the mobility but also the safety of the rural population. To bridge the gap and ensure access to essential infrastructure, Aurobindo Pharma Foundation has laid roads and installed solar streetlights in many villages. This has led to improved mobility between villages, transport of goods & agricultural produce, safer daily commutes of students to schools and regular commutes of villagers, particularly elder people as well as the night time commutes and travels of rural communities, which has contributed to an improved rural landscape, rural economy and livelihoods thereby addressing the needs of the vulnerable/marginalized stakeholder groups. Additionally, the usage of solar streetlight has created long-lasting infrastructure that is environmentally conscious in rural areas.

Furthermore, after the project is completed, the project is assessed by an expert third party organisation (as per CSR Policy and MCA guidelines) to highlight & quantify the impact as well as identify any challenges which further engages the stakeholder groups, contributes to the sustainability of the project, and helps with future project planning.

Principle 5 | Businesses should respect and promote human rights

Section	Principle	Indicator Type
Section C	Principle 5	Essential Indicators

1. **Employees and workers who have been provided training on human rights issues and policy(ies) of the entity**

Category	FY 2026			FY 2025		
	Total	No. of employees/ workers covered	%	Total	No. of employees/ workers covered	%
Employees						
Permanent	29,209	29,209	100%	27,707	27,707	100%
Other than permanent	-	-	-	-	-	-
Total Employees	**29,209**	**29,209**	**100%**	**27,707**	**27,707**	**100%**
Workers						
Permanent	-	-	-	-	-	-
Other than permanent	17,246	-		13,043	-	-
Total Workers	**17,246**	**-**	**-**	**13,043**	**-**	**-**

Note: Existing employee were imparted refresher training, new employees are trained under Auro Swagath programme.

2. Details of minimum wages paid to employees and workers

Category	FY 2026					FY 2025				
	Total	Equal to Minimum wage No.	%	More than minimum wage No.	%	Total	Equal to Minimum wage No.	%	More than minimum wage No.	%
Employees										
Permanent										
Male	26,311	-	-	26,311	100%	24,965	-	-	24,965	100%
Female	2,898	-	-	2,898	100%	2,742	-	-	2,742	100%
Other than permanent										
Male	-	-	-	-	-	-	-	-	-	-
Female	-	-	-	-	-	-	-	-	-	-
Workers										
Permanent										
Male	-	-	-	-	-	-	-	-	-	-
Female	-	-	-	-	-	-	-	-	-	-
Other than permanent										
Male	13,819	5,615	41%	8,205	59%	10,653	3,896	37%	6,757	63%
Female	2,898	504	15%	2,923	85%	2,390	353	15%	2,037	85%

3A: Details of remuneration/salary/wages

Category	Male		Female	
	Number	Median remuneration/ salary/ wages of respective category	Number	Median remuneration/ salary/ wages of respective category
Board of Directors (BOD)	2	INR 62.2 Mn	-	-
Key Managerial Personnel	4	INR 45.7 Mn	-	-
Employees other than BOD and KMP	26,311	INR 0.91 Mn	2,898	INR 1.84Mn
Workers	13,819	INR 0.16 Mn	3,427	INR 0.14Mn

Note:

a) Considering the female employee headcount and remuneration in international subsidiaries, female employee median is high

b) KMP includes 2 directors part of Board

3B: Gross wages paid to females as % of total wages paid by the entity, in the following format:

	FY26	FY25
Gross wages paid to females as % of total wages	16.95%	19.14%

4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

Yes. Employee Grievance Redressal Committee is constituted to address the grievances of employees apart from the on-line platform i.e. People Care Link. Similarly, the Contract Workmen are also encouraged to express/ share their views / ideas / concerns freely at workplace/meetings.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

Yes. Every employee has a right to report grievances, non-compliance or concern through 'People Care Link' in HRMS and through other means like dedicated hotline connect number and dedicated mailbox

6. Number of Complaints on the following made by employees and workers

Particulars	FY 2026			FY 2025		
	Filed during the year	Pending resolution at the end of the year	Remarks	Filed during the year	Pending resolution at the end of the year	Remarks
Sexual Harassment	-	-	-	-	-	-
Discrimination at workplace	-	-	-	-	-	-
Child Labour	-	-	-	-	-	-
Forced Labour/Involuntary Labour	-	-	-	-	-	-
Wages	-	-	-	-	-	-
Other human rights related issues	-	-	-	-	-	-

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

	FY26	FY25
Total Complaints reported under Sexual Harassment on of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	-	-
Complaints on POSH as a % of female employees / workers	-	-
Complaints on POSH upheld	-	-

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

The company has Vigil Mechanism/Whistle Blower Policy and Policy on Sexual Harassment of Women at Workplace in place.

To protect identity of the complainant, the Vigilance and Ethics Officer will not issue any acknowledgement to the complainants, and they are further advised not to write their name / address on the envelope and not to enter into any further correspondence with the Vigilance and Ethics Officer. All records and reports associated with protected disclosures are considered confidential information and access is restricted to the Whistle blower and Vigilance Officer.

The complainant or witnesses involved in the case will not be victimized or discriminated against dealing with complaints of sexual harassment. The Internal Complaints Committee (ICC) or Regional-ICC either collectively or individually will keep the complaint confidential and discreet including the names of the people involved till the case is concluded considering the serious ramifications on both the parties involved in such cases.

9. Do human rights requirements form part of your business agreements and contracts?(Yes/No)

Yes, basis the nature of contract, human rights requirements form part of business agreements and contracts on need basis.

10. Assessment for the year

Particulars	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour	100% of manufacturing and R&D facilities of the group are assessed by entity or statutory authorities or third-party audits
Forced/involuntary labour	
Sexual harassment	
Discrimination at workplace	
Wages	

11. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 9 above.

There were no significant risks / concerns arising from the assessments at question 9 above.

Section	Principle	Indicator Type
Section C	Principle 5	Leadership Indicators

1. **Details of a business process being modified / introduced as a result of addressing human rights grievances /complaints.**

   Not Applicable

2. **Details of the scope and coverage of any Human rights due diligence conducted.**

   As per the Human Rights policy, compliance to human rights is regularly monitored and reviewed by the corporate HR with top management on an annual basis.

3. **Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?**

   Yes

4. **Details on assessment of value chain partners**

Category	% of value chain partners (by value of business done with such partners) that were assessed
Sexual Harassment	-
Discrimination at workplace	
Child Labour	100% of critical suppliers are communicated and screenedon these parameters as a part of vendor qualification and vendor audit procedures and supplier code of conduct. ~77% of key starting material suppliers in India of finished dosage forms (drug product) are assessed on Suppliers Code of Conduct in FY26
Forced Labour/Involuntary Labour	
Wages	-

5. **Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 4 above.**

   Not Applicable as no major significant risks/concerns identified

Principle 6	Businesses should respect and make efforts to protect and restore the environment

Section	Principle	Indicator Type
Section C	Principle 6	Essential Indicators

1. **Details of total energy consumption (in Joules or multiples) and energy intensity**

Particulars	FY 2026	FY 2025
From renewable sources (in GJ)		
Total electricity consumption (A)	6,12,900	3,52,497
Total fuel consumption (B)	5,53,567	4,24,119
Energy consumption through other sources (C)	-	-
Total energy consumed from renewable sources (A+B+C)	11,66,467	7,76,616
From non-renewable sources (in GJ)		
Total electricity consumption (D)	27,09,767	23,75,323
Total fuel consumption (E)	90,56,787	73,84,539
Energy consumption through other sources (F)	51,285	-
Total energy consumed from non-renewable sources (D+E+F)	1,18,17,853	97,59,861

Particulars	FY 2026	FY 2025
Total energy consumption	1,29,84,302	1,05,36,477
Energy intensity per rupee of turnover (Total energy consumption/turnover in INR Mn)	38.87	33.21
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)[1] (Total energy consumed/Revenue from operations adjusted for PPP) (GJ/Revenue Mn) adjusted to PPP	790.59	686.19
Energy intensity in terms of physical output (GJ/ Production in MT)	525.80	429.95

[1] PPP – IMF conversion factors for FY2026- 20.34 and FY2025- 20.66 (Source:https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)

Revenue for calculating intensity is considered excluding service income

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - Yes, independent assurance was carried out by M/s Sharp & Tannan Associates

2. **Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any.**

   Not Applicable

3. **Provide details of the following disclosures related to water**

Parameter	FY 2026	FY 2025
Water withdrawal by source (in kilolitres)		
(i) Surface water	-	-
(ii) Ground water	20,78,729	20,81,641
(iii) Third party water	24,93,091	25,10,947
(iv) Seawater / desalinated water	18,30,897	52,82,064
(v) Others		-
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)	64,02,717	55,43,209
Total volume of water consumption (in kilolitres)	64,02,717	55,43,209
Water intensity per rupee of turnover (Water consumed / turnover INR Mn)	19,17	17.47
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)1 (Total water consumption in kilolitres / Revenue from operations adjusted for PPP in INR Million)	389.85	361.00
Water intensity in terms of physical output (Total water consumption in KL/ Production in MT)	259.28	226.20

[1] PPP – IMF conversion factors for FY2026- 20.34 and FY2025- 20.66 (Source:https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)

Revenue for calculating intensity is considered excluding service income

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - Yes, independent assurance was carried out by M/s Sharp & Tannan Associates

4. **Provide the following details related to water discharged:**

Parameter	FY 2026	FY 2025
Water discharge by destination and level of treatment (in kilolitres)		
(i) To Surface water		
- No treatment	-	-
- With treatment	-	-
(ii) To Groundwater		
- No treatment	-	-
- With treatment	-	-
(iii) To Seawater		
- No treatment	-	-
- With treatment – Primary & secondary treatment	5,79,568	2,01,295

Parameter		FY 2026	FY 2025
(iv)	Sent to third-parties		
	- No treatment	-	-
	- With treatment – Primary & secondary treatment	7,58,883	6,27,344
(v)	Others		
	- No treatment	-	-
	- With treatment – please specify level of treatment	-	-
Total water discharged (in kilolitres)		**13,38,451**	**8,28,639**

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

Yes. Our fully operational Effluent Treatment Plants (ETPs) deploy innovative technologies to collect, store, treat, and manage wastewater across all our units, and we have achieved Zero Liquid Discharge status at four units namely – Apitoria Unit-1, Apitoria Unit-2, Apitoria Unit-3 and Apitoria Unit-5. We use treated wastewater for utility consumption.

6. Provide details of air emissions (other than GHG emissions) by the entity

Parameter	Units	FY 2026	FY 2025
NOx	Metric Tonnes	941	405
SOx	Metric Tonnes	1234	797
Particulate matter (PM)*	Metric Tonnes	428	206
Persistent organic pollutants (POP)	-	-	-
Volatile organic compounds (VOC)	-	-	-
Hazardous air pollutants (HAP)	-	-	-

*Suspended Particulate Matter

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - No

7. Details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity

Parameter	Unit	FY 2026	FY 2025
Total Scope 1 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tonnes of CO2 equivalent	9,12,276	7,50,616
CO2 Emissions	Metric tonnes	8,64,623	7,19,629
CH4 Emissions	Metric tonnes	84	71
N2O Emissions	Metric tonnes	12	12
Hydrofluorocarbon (HFC)	Metric tonnes of CO2 equivalent	29,344	23,147
Hydrochlorofluorocarbon (HCFC)	Metric tonnes of CO2 equivalent	980	2,026
Total Scope 2 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tonnes of CO2 equivalent	5,33,286	4,74,772
Total Scope 1 and Scope 2 emissions per Mn rupee of turnover	MT/INR Mn	4.32	3.86
Total Scope 1 and Scope 2 emission intensity per INR Mn of turnover adjusted for Purchasing Power Parity (PPP)1	MT/Mn Revenue adjusted to PPP	88.02	79.80
Total Scope 1 and Scope 2 emission intensity in terms of physical output	MT/Production2 in Mn	58.54	50

[1] PPP – IMF conversion factors for FY2026- 20.34 and FY2025- 20.66 (Source:https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)

Revenue for calculating intensity is considered excluding service income

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - Yes, independent assurance was carried out by M/s Sharp & Tannan Associates

8. Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details.

Yes. As part of our GHG emission reduction, we have implemented multiple projects for reducing greenhouse gas emissions from our operations. Those include

- Generation and use of renewable energy (Solar)- we have generated and consumed about 40,455 MWh of solar from our 30MW Solar power plant
- Sourcing of renewable energy from our associates
- Shifting to Biomass or Briquette fuel in place of coal at some of our units
- Use of Piped Natural Gas.
- Apart from the above we also take-up various Energy conservation initiatives every year at manufacturing units for reducing energy consumption and in-turn GHG emissions reduction.

This has resulted in emission reduction about 4,85,661 tonnes of CO2 equivalent.

9. Provide details related to waste management by the entity

Parameter	FY 2026	FY 2025
Total Waste generated (in metric tonnes)		
Plastic waste (A)	924	837
E-waste (B)	15	3
Bio-medical waste (C)	403	354
Construction and demolition waste (D)	-	-
Battery waste (E)**		
Radioactive waste (F)	-	-
Other Hazardous waste (G)		
(i) Other Hazardous Waste	29,467	23,535
(ii) Used Oil	22	29
Other Non-hazardous waste generated (H)		
Fly Ash	57,304	30,780
Total (A+B + C + D + E + F + G+ H)	**88,135**	**55,538**
Waste intensity per rupee of turnover (Total waste generated / Revenue from operations INR Mn)	0.26	0.18
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total waste generated / Revenue from operations adjusted for PPP[1])	5.37	3.62
Waste intensity in terms of physical output (Total waste generated in MT/ Production in Mn2)	3.57	2.27
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)		
Category of waste		
(i) Recycled		
Plastic Waste #	924	837
Fly Ash ##	57,304	30,780
E-Waste #	15	3
Battery Waste ###	**	**
(ii) Re-used	-	-
(iii) Other recovery operations	-	-
Total	**58,243**	**31,620**

Parameter		FY 2026	FY 2025
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)			
Category of waste			
(i)	Incineration	509	1,220
(ii)	Landfilling	10,031	4,781
(iii)	Other disposal operations (MT of Hazardous Waste disposed to Cement units for use as alternative fuel)	18,927	17,534
Total		**29,467**	**23,535**

*Information pertaining to demolition and construction waste is not available with the company

**Count of battery waste generated is 4,101 for FY 2026 and Nos. 4,101 for FY 2025. Since the battery waste details are not available in MT, the same is not considered for total calculation

Disposed for recycling to authorised recyclers

Disposed to brick manufacturers for recycling

Disposed under buyback for recycling

[1] PPP – IMF conversion factors for FY2026- 20.34 and FY2025- 20.66 (Source:https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)

Revenue for calculating intensity is considered excluding service income

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - Yes, independent assurance was carried out by M/s Sharp & Tannan Associates

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

The Company integrates a waste management plan with a comprehensive approach towards waste minimization, segregation and safe disposal as part of hazardous waste disposal mechanism, the Company has implemented initiatives of diverting larger quantity of hazardous waste towards co-processing and recycling over other disposal mechanisms that is incineration and landfilling. We have waste management systems in place at all our facilities. Plastic waste is either co-processed or recycled based upon the type of waste generated. E-waste is sold to authorized vendors. More than 66% of our hazardous waste is sent to cement industries and recyclers for co-processing and recycling. Other non-hazardous waste such as glass, MS scrap, wood waste, boiler ash etc. is sent to recyclers.

11. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required

None of the company operations/offices are located in ecologically sensitive areas

12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

No environmental impact assessments were made during FY26

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances

Not Applicable as the company follows all applicable environmental laws, regulations and guidelines

Section	Principle	Indicator Type
Section C	Principle 6	Leadership Indicators

1. Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):

For each facility / plant located in areas of water stress, provide the following information:

(i) Name of the area - Bhiwadi, Rajasthan

(ii) Nature of operations – Manufacturing of injectables

(iii) Water withdrawal, consumption and discharge

Parameter	FY 2026	FY 20255
Water withdrawal by source (in kilolitres)		
(i) Surface water		-
(ii) Groundwater	42,563	26,806
(iii) Third party water	18,580	-
(iv) Seawater / desalinated water	-	-
(v) Others	-	-
Total volume of water withdrawal (in kilolitres)	61,143	26,806
Total volume of water consumption (in kilolitres)	61,143	26,806
Water intensity per rupee of turnover (Water consumed / INR Mn turnover)	0.18	0.08
Water discharge (in kilolitres)		
(i) Into Surface water		
- No treatment	-	-
- With treatment	-	-
(ii) Into Groundwater		
- No treatment	-	-
- With treatment	-	-
(iii) Into Seawater		
- No treatment	-	-
- With treatment	-	-
(iv) Sent to third parties		
- No treatment	-	-
- With treatment	23,257KL	26,091 KL
(v) Others		
- No treatment		-
- With treatment	-	-
Total water discharged (in kilolitres)	**23,257KL**	**26,091 KL**

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - No

2. Please provide details of total Scope 3 emissions & its intensity, in the following format:

Parameter	Unit	FY 2026	FY 2025*
Total Scope 3 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tonnes of CO2 equivalent	6,06,351	3,60,221
Total Scope 3 emissions per Mn rupee of turnover	MT/INR Mn	1,82	1.14
Total Scope 3 emission intensity per INR Mn of turnover adjusted for Purchasing Power Parity (PPP)1	MT/Mn Revenue adjusted to PPP	36,92	23.45
Total Scope 3 emission intensity in terms of physical output	MT/Production in MT	24.55	14.70

For the calculation of Scope 3 emissions, we considered eight relevant categories as per GHG Protocol, which includes Purchased Goods and Services, Capital Goods, Fuel- and Energy-Related Activities, , Waste Generated in Operations, Business Travel, Employee Commute, and Downstream Transportation and Distribution.

By conducting this Scope 3 emissions inventory, the company aims to identify key areas for improvement and implement strategies to reduce our carbon footprint across the entire value chain.

Scope 3 emission categories	Emissions (tCO2e)
Purchased Goods and Services	81,297
Purchase of Capital Goods	3,638
Fuel and Energy Related Activities (not incl. in Scope 1 or Scope 2)	3,64,215
Waste Generated in Operations	11,447
Business Travel	5,960
Employee commute*	11,119
Upstream leased assets	1,842
Downstream Transportation	1,26,833
Total Scope 3 emissions	6,06,351

*Employee commute covers more than 70% of employees in Indian entities

Revenue for calculating intensity is considered excluding service income

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency- Not Applicable

3. With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities.

Not Applicable

4. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, provide details of the same as well as outcome of such initiatives

Sl. No	Initiative undertaken	Details of the initiative (Web-link, if any, may provided along-with summary)	Outcome of the initiatve
1	Synchronization of utility equipments & other energy conservation initiatives	• Synchronization of chilled water system • Synchronization of Nitrogen plant • Installation of Variable Frequency Drive(VFDs) for utility pumps • Chiller Efficiency enhancement by introducing BOOT model • Installation of Automatic Power Factor Control (APFC) panel	194 Lakh KWH of electricity saved across API and FDF divisions
2	Combustion control system for boilers	• Optimization of coal consumption by combustion control system automation • Flash jet pump for recovering flash steam and pumping the condensate to boiler • Recovery of Gland vent condenser(GVC) heat for feed water temperature	1185 MT of coal saved across API units
3	Installation of CHPs	Installation of 3 Combined Heat and Power plant at Apitoria Unit-1, Apitoria Unit-4, Lyfius	Energy conservation and avoiding of GHG emissions
4	Green manufacturing initiatives	At Lyfius, fermentation technology is used for manufacturing of 6-Amino Penicillanic Acid (6-APA). The process begins with fermentation-based production of Penicillin and followed by enzymatic conversion to 6-APA. At Apitoria Unit-5, enzymatic process is used for manufacture of Amoxicillin and Ampicillin	Eliminates consumption of solvents

5. Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link.

Yes, the company has a business continuity and on-site emergency plan for all its locations. This business continuity plan enables the Company to adapt in situations arising from any natural calamity or an unprecedented event which may disrupt the business operations. Company continuously enhances its existing plan by incorporating interferences and observations from disruptions faced in the unprecedented situations such as the pandemic. Further, the company's risk management plan enables the minimization of disaster-linked losses, by assessing the potential for major disruption with its consequent risks to the business, and by providing the appropriate mitigation action plans.

6. **Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard**

   There are no significant adverse impacts to the environment arising from value chain of the entity.

7. **Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.**

   About 77% of key starting material suppliers for finished dosage forms (drug products) in India are screened for sustainable practices.

8. **How many Green Credits have been generated or procured: (FY25)**

   a. By the listed entity - Nil

   b. By the top ten (in terms of value of purchases and sales, respectively) value chain partners - 0

Principle 7	**Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent**

Section	Principle	Indicator Type
Section C	Principle 7	Essential Indicators

1. A. **Number of affiliations with trade and industry chambers/ associations. – 48**

   B. **List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to.**

Sl. No	Name of the trade and industry chambers/ associations	Reach of trade and industry chambers/ associations
1	Federation of Indian Micro and Small and Medium Enterprises (FIMSE)	National
2	Confederation of Indian Industry	National
3	Indian Chamber of Commerce & Industry	National
4	Pharmaceuticals Export Promotion Council of India	National
5	Pharmaceutical Supply Chain Initiative	International
6	The Federation TG and AP Chambers of Commerce & Industry (FAPCCI)	State
7	The Federation of Telangana Chambers of Commerce and Industry	State
8	Indo American Chamber of Commerce	National
9	AMR Industry Alliance	International
10	Indian Drug Manufacturers Association	National

2. **Provide details of corrective action taken or underway on any issues related to anti- competitive conduct by the entity, based on adverse orders from regulatory authorities**

   No adverse orders were received from regulatory authorities

Section	Principle	Indicator Type
Section C	Principle 7	Leadership Indicators

1. **Details of public policy positions advocated by the entity:**

   The company through trade and industry associations makes representation to the government/regulators on various aspects considering public interest at large.

Principle 8	Businesses should promote inclusive growth and equitable development

Section	Principle	Indicator Type
Section C	Principle 8	Essential Indicators

1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.

Name and brief details of project	SIA Notification No. & Date	Whether conducted by independent external agency(Yes/No)	Results in public domain (Yes/No)	Relevant Web link
Impact Assessment Report of Multipurpose Community Hall, Kasimkota Village, Anakapalli District, Andhra Pradesh	G.S.R. 40(E) of Ministry of Corporate Affairs – 22.01.2021	Yes. Assessment conducted and reported by Mahila Abhivruddhi Society, Andhra Pradesh (APMAS)	Yes	Link: aurobindo.com/sustainability/impact-assessment-reports-csr-projects
Impact Assessment Report of Aurobindo Skill Development Centre, Indrakaran Village, Sangareddy District, Telangana	G.S.R. 40(E) of Ministry of Corporate Affairs – 22.01.2021	Yes. Assessment conducted and reported by Mahila Abhivruddhi Society, Andhra Pradesh (APMAS)	Yes	Link: aurobindo.com/sustainability/impact-assessment-reports-csr-projects
Impact Assessment Report of Dining Hall, Kitchen Block with Kitchen Equipment at Vidya Bharathi Vignana Kendram School, Nadergul Village, Ranga Reddy District, Telangana	G.S.R. 40(E) of Ministry of Corporate Affairs – 22.01.2021	Yes. Assessment conducted and reported by Mahila Abhivruddhi Society, Andhra Pradesh (APMAS)	Yes	Link: aurobindo.com/sustainability/impact-assessment-reports-csr-projects

2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity

Not Applicable

3. Describe the mechanisms to receive and redress grievances of the community.

All the requests/applications from Villagers/Gram Sabha's / Panchayat / Ward Members/NGOs/Trusts/ Societies/ Beneficiaries etc. shall be scrutinized and screened by CSR Cell and then their need assessment would be done. The need assessment/baseline survey shall be carried out through in-house expertise and resources. However, in case of specialized CSR projects/activities for which in-house capacity is not available, the baseline survey/need assessment shall be carried out by specialized agencies. In any case, the Company shall maintain the documentary evidence of having got the need assessment study done through its own expertise and resources, or through some specialized agencies, or having accessed reliable data in this regard from recognized authoritative secondary sources.

The implementation and monitoring of the CSR activities shall be overseen by the CSR Committee of the Board. The day-to-day implementation shall be under the overall supervision of a senior level executive, one rank below the Board Level, who shall act as the Nodal Officer. A CSR team of officials/employees within the organization who shall execute the CSR activities. The Nodal Officer along with a team of officials/employees shall coordinate & implement the CSR activities. For effective delivery of CSR operations and to have a focused approach, Aurobindo Pharma Foundation has been formed as a trust and Section 8 company under relevant legal framework. The team of CSR will work in close coordination under foundation and perform different activities. The CSR Committee and the Nodal Officer's team of officers/ employees together will constitute the two-tier organizational structure to steer the CSR agenda of the company. If required, the consultation/help of State Government/District administration may be taken wherever necessary.

4. Percentage of input material (inputs to total inputs by value) sourced from suppliers:

Particulars	FY 2026	FY 2025
Directly sourced from MSMEs/ small producers	10.51%	12.09%
Sourced directly from within the district and neighbouring districts	19%	18%

5. **Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost**

Location	FY 2026 Current Financial Year	FY 2025 Previous Financial Year
Rural	81.38%	81.73%
Semi-Rural	4.68%	3.58%
Urban	1.67%	2.05%
Metropolitan	12.27%	12.65%
(Place to be categorized as per RBI Classification System - rural / semi urban / urban / metropolitan)		

Section	Principle	Indicator Type
Section C	Principle 8	Leadership Indicators

1. **Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above):**

   There are no negative impacts as per the assessment made

2. **Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:**

Sl. No.	State	Aspirational District	Amount spent (In INR)
1	Andhra Pradesh	YSR Kadapa	1 Mn

3. A. **Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No)**

   No. The company doesn't have a preferential procurement policy to purchase from suppliers comprising marginalized/vulnerable groups. Selection of supplier is driven by vendor qualification process for critical material procurement.

   B. **From which marginalized /vulnerable groups do you procure?**

   Not Applicable

   C. **What percentage of total procurement (by value) does it constitute?**

   Not Applicable

4. **Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge:**

   The Company does not derive any benefits from intellectual properties owned or acquired based on traditional knowledge.

5. **Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes wherein usage of traditional knowledge is involved.**

   Not Applicable

6. Details of beneficiaries of CSR Projects:

Sl. No.	CSR Project	No. of persons benefitted from CSR Projects	% of beneficiaries from vulnerable and marginalized groups
1	Health & Sanitation projects (supported Aurobindo Health Clinics, provided ambulances to government hospitals, supported health camps, supported underprivileged patients, executed improved solid waste management practices in rural areas)	4,03,433	100%
2	Rural Development projects (established multi-purpose community halls, laid CC roads, installed solar street lights, etc.)	79,196	100%
3	Art, Culture, and Heritage projects (provided support for conducting events in schools and villages to promote Indian traditional art, music, dance, etc.)	45,250	100%
4	Public Safety projects (constructed infrastructure for police academy, provided equipment and infrastructure to police stations and fire safety associations)	1,00,224	100%
5	Nutrition projects (supported distribution of free nutritious breakfast meals in Government schools, distributed meals in government hospitals, market yards, government supported canteens, etc.)	57,312	100%
6	Safe Drinking Water projects (established various rural drinking water systems such as RO Water Plant with shed, overhead water tank, etc.)	57,139	100%
7	Animal Welfare projects (supported gowshalas and animal husbandry camps in rural areas)	44,553	100%
8	Education projects (Constructed additional classrooms, toilets, etc., in governments schools & colleges, provided infrastructure to government schools, colleges, and universities, distributed Books, Bags,stationery and other material to students of government schools, supported the education of underprivileged students, supported skill development of rural unemployed youth & women)	86,134	100%
9	Sustainable Agriculture projects (supported Farmer Producer Organisations, supported skill development and capacity building of small, marginal farmers)	9,893	100%
10	Rural Sports projects (supported underprivileged athletes, supported for the organising district and mandal level sports competitions	471	100%
11	Environmental Sustainability projects (developed ponds, de-silted ponds, cleared debris, weeds from canals, etc.)	13,000	100%

Principle 9	**Businesses should engage with and provide value to their consumers in a responsible manner**

Section	Principle	Indicator Type
Section C	Principle 9	Essential Indicators

1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback.

All the queries and product-related safety complaints are addressed on a priority basis. All spontaneous adverse events (marketed products) are collected via phone, email, fax, postal and Aurobindo official website. All adverse events (investigational products) are collected as per the Clinical Trial Protocol or Safety Management Plan. For this purpose, various channels of communication are available to collect safety information round the clock. All employees of the company participating in the pharmacovigilance activities are trained, know their responsibility and are capable to perform their duties. We comply with international regulations governing the reporting, analysis and communication of side effects. We have a governance framework and policies in place to help us detect and act on any side- effects and other human safety information that may be associated with our products. We are using Argus Safety database to support identification and evaluation of safety information, for example, the identification of new side effects or a change in the nature, frequency, or severity of known side effects.

2. **Turnover of products and/ services as a percentage of turnover from all products/service that carry information about:**

Particulars	As a percentage to total turnover
Environmental and social parameters relevant to the product	-
Safe and responsible usage	100%
Recycling and/or safe disposal	-

3. **Number of consumer complaints in respect of the following:**

Particulars	FY 2026			FY 2025		
	Received during the year	Pending resolution at end of year	Remarks	Received during the year	Pending resolution at end of year	Remarks
Data privacy	-	-	-	-	-	-
Advertising	-	-	-	-	-	-
Cyber-security	-	-	-	-	-	-
Delivery of essential services	-	-	-	-	-	-
Restrictive Trade Practices	-	-	-	-	-	-
Unfair Trade Practices	-	-	-	-	-	-
Other	-	-	-	-	-	-

4. **Details of instances of product recalls on account of safety issues:**

Particulars	Number	Reasons for recall
Voluntary recalls	6	Reasons for recall of products are due to quality specifications
Forced recalls	-	-

5. **Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/ No) If available, provide a web-link of the policy.**

Policy on cyber security is available to address risks related to information security and data privacy. The company has been certified with the ISO 27001:2022 (information security).

6. **Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.**

Root cause identification and Investigation is performed, and corrective and preventive actions are initiated to prevent re-occurrence of product recalls

7. **Provide the following information relating to data breaches:**

a. Number of instances of data breaches – Nil

b. Percentage of data breaches involving personally identifiable information of customers – 0%

c. Impact, if any, of the data breaches – Not Applicable

Section	Principle	Indicator Type
Section C	Principle 9	Leadership Indicators

1. **Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available).**

Link :https://www.aurobindo.com/about-us/business-units/formulations

2. **Steps taken to inform and educate consumers about safe and responsible usage of products and/ or services.**

Educational materials explain the role and responsibilities of Health Care Professionals in identifying and evaluating side effects and other human safety information, and subsequently preparing and submitting reports of high quality.

3. Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.

The benefit/risk profile of an Aurobindo product is assessed throughout its lifecycle using a benefit/risk framework and appropriate analyses. When information is found that changes the benefit/risk balance in a negative direction, action is taken to characterise, communicate and minimise the risk. Proposed actions are discussed with regulatory authorities and can include modifying the prescribing information (which includes the patient information leaflet), sending communications to Health Care Professionals (HCPs) and sometimes carrying out further Post Authorization Safety Studies and/or other risk management measures. In certain cases, it may be appropriate to withdraw the medicine from the market.

4. Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable) If yes, provide details in brief. Did your entity carry out any survey with regard to consumer satisfaction relating to the major products / services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No)

No

87 Nariman Bhavan
227 Nariman Point
Mumbai 400 021
India
+91 22 6153 7500; 2202 2224 / 8857
www.sharpandtannan.com

SHARP & TANNAN ASSOCIATES
chartered accountants

To the Board of Directors,
Aurobindo Pharma Limited,
Galaxy, Floors: 22-24 Plot No.1,
Survey No.83/1 Hyderabad Knowledge City,
Raidurg Panmaktha, Hyderabad, 500032
(CIN - L24239TG1986PLC015190)

Independent practitioner's reasonable assurance report on identified sustainability information in Aurobindo Pharma Limited BRSR Core

We have undertaken to perform a reasonable assurance engagement, for Aurobindo Pharma Limited on consolidated basis, (hereinafter abbreviated as "the Company") vide Engagement Letter dated 14th May 2026 in respect of the agreed Sustainability Information listed below (the "Identified Sustainability Information") in accordance with the criteria stated below. This Identified Sustainability Information as included in the BRSR Core of the Company for the financial year ended 31st March 2026. This engagement was conducted by a multidisciplinary team including assurance practitioners, engineers and other professionals.

Identified Sustainability Information

The Identified Sustainability Information for the financial year ended 31st March 2026 is summarized below:

Attribute	Principle	Key Performance Indicator
Energy Footprint	Principle 6 –1	• Total energy consumption (in Joules or multiples) and energy intensity • Energy consumed from renewable and non-renewable sources
Water Footprint	Principle 6 – 3	• Total water consumption • Water consumption intensity
	Principle 6 – 4	• Total water consumption & water consumption intensity • Water discharge by destination & level of treatment
Greenhouse (GHG) footprint	Principle 6 – 7	• Greenhouse gas emissions (Scope 1 & Scope 2 emissions) & its intensity
Embracing circularity – details related to waste management by the entity	Principle 6 – 9	• Details related to waste generated by the entity (category wise) • Waste intensity • Each category of waste generated, total waste recovered through recycling, re-using or other recovery operations • For each category of waste generated, total waste disposed by nature of disposal method
Enhancing Employee Wellbeing and Safety	Principle 3 - 1(c)	• Spending on measures towards well-being of employees and workers (including permanent and other than permanent)
	Principle 3 – 11	Safety related incidents: • Lost time Injury Frequency Rate (LTIFR) (per one million-person hours worked) • Total recorded work-related injuries • No. of fatalities • High consequence work-related injury or ill-health (excluding fatalities)

87 Nariman Bhavan
227 Nariman Point
Mumbai 400 021
India
+91 22 6153 7500 ; 2202 2224 / 8857
www.sharpandtannan.com

SHARP & TANNAN ASSOCIATES
chartered accountants

Attribute	Principle	Key Performance Indicator
Enabling gender diversity in business	Principle 5 - 3(b)	Gross wages paid to females as % of total wages paid by the entity
	Principle 5 - 7	Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013
Enabling inclusive development	Principle 8 - 4	Input material sourced from following sources as % of total purchases – Directly sourced from MSMEs/ small producers and from within India
	Principle 8 - 5	Job creation in smaller towns – Wages paid to persons employed in smaller towns (permanent or nonpermanent /on contract) as % of total wage cost
Fairness in Engaging with Customers and Suppliers	Principle 9 - 7	Instances involving loss / breach of data of customers as a percentage of total data breaches or cyber security events
	Principle 1 - 8	Number of days of accounts payable
Openness of business	Principle 1 - 9	Concentration of purchases & sales done with trading houses, dealers, and related parties Loans and advances & investments with related parties

Our reasonable assurance engagement was with respect to the financial year ended 31st March 2026 information only and we have not performed any procedures with respect to earlier periods or any other elements included in the BRSR/ BRSR Core and, therefore, do not express any opinion thereon.

Criteria

The criteria used by the Company to prepare the Identified Sustainability Information for the financial year ended 31st March 2026 are the BRSR Core – 'Framework for assurance and ESG disclosures for value chain' and BRSR format, issued under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR Regulations') read with SEBI circular SEBI/HO/CFD/CFD- SEC-2/P/CIR/2023/122 dated 12 July 2023 ("SEBI Circular") and the Guidance note for BRSR read with National Guidelines for Responsible Business Conduct issued by Ministry of Corporate Affairs ("BRSR Framework") (hereinafter referred to as 'Criteria'). Further, the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations") in this regard, have been amended vide notification No. SEBI/LAD-NRO/GN/2025/239 dated March 27, 2025, which came into force on March 28, 2025.

Management's Responsibility

The Company's management is responsible for selecting or establishing suitable criteria for preparing the Sustainability Information, taking into account applicable laws and regulations, if any, related to reporting on the Sustainability Information, Identification of key aspects, engagement with stakeholders, content, preparation and presentation of the Identified Sustainability Information in accordance with the Criteria. This responsibility includes design, implementation and maintenance of internal control relevant to the preparation of the BRSR and the measurement of Identified Sustainability Information, which is free from material misstatement, whether due to fraud or error.

Inherent limitations

The absence of a significant body of established practice on which to draw, to evaluate and measure non-financial information allows for different, but acceptable, measures and measurement techniques and can affect comparability between entities.

The preparation of the Company's BRSR information requires the management to establish or interpret the criteria, make determinations about the relevancy of information to be included, and make estimates and assumptions that affect the reported information.

Measurement of certain amounts and BRSR metrics, some of which are estimates, is subject to substantial inherent measurement uncertainty, for example GHG emissions, water footprint, energy footprint. Obtaining sufficient appropriate evidence to support our opinion/ conclusion does not reduce the uncertainty in the amount and metrics.

S&TA (the Firm) has not been involved in evaluation or assessment of any financial data/performance of the Company. S&TA's opinion on specific BRSR Core indicators (reference- all sections of core indicators where currency; INR has been applied) relies on the third party audited financial reports of the Company. S&TA

87 Nariman Bhavan
227 Nariman Point
Mumbai 400 021
India
+91 22 6153 7500; 2202 2224 / 8857
www.sharpandtannan.com

SHARP & TANNAN ASSOCIATES
chartered accountants

does not take any responsibility of the financial data reported in the audited financial reports of the Company.

Our Independence and Quality Control

We have maintained our independence and confirm that we have met the requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India and have the required competencies and experience to conduct this assurance engagement.

The Firm applies Standard on Quality Control (SQC) 1, "Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements", and accordingly maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards, and applicable legal and regulatory requirements.

Our Responsibility

Our responsibility is to express a reasonable assurance opinion on the Identified Sustainability Information based on the procedures we have performed and evidence we have obtained.

We conducted our engagement in accordance with the Standard on Sustainability Assurance Engagements (SSAE) 3000, "Assurance Engagements on Sustainability Information", issued by the Sustainability Reporting Standards Board of the Institute of Chartered Accountants of India. This standard requires that we plan and perform our engagement to obtain reasonable assurance about whether the Identified Sustainability Information are prepared, in all material respects, in accordance with the Reporting Criteria.

A reasonable assurance engagement involves assessing the risks of material misstatement of the Identified Sustainability Information whether due to fraud or error, responding to the assessed risks as necessary in the circumstances.

The procedures we performed were based on our professional judgment and included inquiries, observation of processes performed, inspection of documents, evaluating the appropriateness of quantification methods and reporting policies, analytical procedures and agreeing or reconciling with underlying records.

Given the circumstances of the engagement, in performing the procedures listed above, we:

- Visited the Corporate Office, APL Healthcare (Unit- 1 & 3) at Hyderabad, Telangana for data and document verification.
- Interviewed senior executives to understand the reporting process, governance, systems and controls in place during the reporting period.
- Reviewed the records and relevant documentation including information from audited financial statements or statutory reports submitted by the Company to support relevant performance disclosures within the Criteria.
- Evaluated the suitability and application of Criteria and that the Criteria have been applied appropriately to the subject matter.
- Selected key parameters and representative sampling, based on statistical audit sampling tables and agreeing claims to source information to check accuracy and completeness of claims such as source data, meter data, etc.
- Re-performed calculations to check accuracy of claims.
- Reviewed data from independent sources, wherever available.
- Reviewed data, information about sustainability performance indicators and statements in the report.
- Reviewed and verified information/ data as per the BRSR Core framework;
- Reviewed accuracy, transparency and completeness of the information/ data provided.
- Taken and relied on the management representation letter given by the management.

Exclusions

Our reasonable assurance scope excludes the following areas, and therefore we do not express an opinion on them:

- Operations of the Company other than those mentioned in the 'Scope of Assurance'.
- Any disclosure other than those mentioned in the Scope above.

87 Nariman Bhavan
227 Nariman Point
Mumbai 400 021
India
+91 22 6153 7500; 2202 2224/8857
www.sharpandtannan.com

SHARP & TANNAN ASSOCIATES
chartered accountants

- Data and information outside the defined reporting period, i.e., 1st April 2025 to 31st March 2026.
- Aspects of the BRSR attributes and the data/ information (qualitative or quantitative) other than the Identified Sustainability Information.
- Data related to the Company's financial performance, strategy, and other related linkages expressed in the Report.
- The Company's statements that describe expressions of opinion, belief, aspiration, expectation, forward-looking statements, and assertions related to Intellectual Property Rights and other competitive issues.
- Mapping of the Report with reporting frameworks other than those specifically mentioned. Any assessments or comparisons with frameworks beyond the specified ones are not considered in this engagement.
- While we considered the effectiveness of management's internal controls when determining the nature and extent of our procedures, our assurance engagement was not designed to provide assurance on internal controls.
- The procedures did not include testing controls or performing procedures relating to checking the aggregation or calculation of data within IT systems.
- Aspects of the Report that fall outside the mentioned scope and boundary are not subject to assurance. The assessment is limited to the defined parameters.
- The assurance engagement does not include a review of legal compliances. Compliance with legal requirements is not within the scope of this assurance, and the Company is responsible for ensuring adherence to relevant laws.
- The assurance engagement is based on the assumption that the data and information provided by the Company are complete, sufficient, and authentic.

Opinion

Based on the procedures we have performed and the evidences we have obtained, the Identified Sustainability Information included in the BRSR Core for the financial year ended 31st March 2026 are prepared in all material respects, in accordance with the Criteria.

Restriction on use

Our Reasonable Assurance report has been prepared and addressed to the Board of Directors of Aurobindo Pharma Limited at the sole request, to assist in reporting on Company's sustainability performance and activities. Accordingly, we accept no liability to anyone, other than the company. Our Deliverables should not be used for any other purpose or by any person other than the addressees of our Deliverables. The firm neither accepts nor assumes any duty of care or liability for any other purpose or to any other party to whom our Deliverables are shown or into whose hands it may come without our prior consent in writing.

Sharp & Tannan Associates
Chartered Accountants
(Firm's Registration No. 109983W)

CA Arnob Choudhuri
(Partner)
(Membership No. 156378)
(UDIN – 26156378ZAIINL6835)

Place: Pune
Date: July 28th, 2026

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.08.03 18:12:41 +05'30'